Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 814-994-6 | CAS number: 123403-95-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
LD50 (oral, rat): > 2000 mg/kg bw
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Wiga GmbH, Germany
- Age at study initiation: young adult animals (approx. 10 weeks)
- Weight at study initiation: Animals of comparable weight (± 20% of the mean weight)
- Fasting period before study: 16 hours before administration
- Housing: single housing
- Diet (e.g. ad libitum): VRF1(P); SDS Special Diets Services, 67122 Altrip, Germany, ad libitum
- Water (e.g. ad libitum): Tap water ad libitum
- Acclimation period: at leasst 5 days before the beginning of the experimental phase
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 30 - 70 %
- Humidity (%): 22°C +/- 3°C
- Air changes (per hr): Approx. 10
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 3
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, pathology - Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality occurred in both 2000 mg/kg bw test groups.
- Clinical signs:
- 2000 mg/kg bw(first test group): two animals showed poor general state from hour 0 until hour 5. Impaired general state was seen in these animals from study day 1 until study day 6, while in the third animal this finding was noticed from hour 0 until hour 5 after administration. Dyspnoea was noted in all animals from hour 0 until hour 5 and persisted in one animal until study day 1. Piloerection was recorded in one animal from hour 0 until hour 5. The same finding was observed in the two other animals from study day 1 until study day 6 after administration. In one animal abdominal position and tremor was seen from hour 0 until hour 5, while atonia was noticed from hour 1 until hour 5 and lacrimation from hour 4 until hour 5. Reduced defecation was noted from day 1 until day 2 in this animal. In another animal lateral position was observed from hour 0 until hour 5, while clonic convulsions were seen from hour 1 until hour 5 in this animal. Furthermore, salivation was recorded from hour 0 until hour 1 and lacrimation from hour 4 until hour 5, while exsiccosis, reduced defecation and chromodacryorrhea was noticed in this animal on study day 1; reduced defecation persisted until day 2. Additional findings in the third animal revealed salivation from hour 0 until hour 1, while cowering position was seen from hour 1 until hour 5 in this animal.
2000 mg/kg bw (second test group): poor general state was seen in all animals from hour 0 until hour 1, 2 or 3, followed by impaired general state from hour 2, 3 or 4 until hour 5 after administration. In all animals dyspnoea and piloerection was observed from hour 0 until hour 2 or 5. Abdominal position was noticed in two animals from hour 0 until hour 1 or 2. Cowering position was seen in these animals from hour 2 until hour 3 or from hour 3 until hour 5. In the third animal this finding was noted from hour 0 until hour 5. In addition, ataxia and tremor was observed in this animal from hour 0 until hour 2 after administration. - Body weight:
- The body weight of one animal in each test group increased within the normal range throughout the study period. The body weights of the two other animals in both test group increased in a normal range during the first observation week but these animals only slightly gained weight during the second week. This effect is observed at times in the rat strain used, because in the required age range the female animals have already reached the phase of slow growth.
- Gross pathology:
- There were no macroscopic pathological findings in any animal sacrificed at the end of the observation period (6 females).
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the conditions of this study the median lethal dose of 3-(1-Ethoxyethyl)-5-methyloxazolidin-2-on after oral administration was found to be greater than 2000 mg/kg bw in rats.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In an acute oral toxicity study performed according to the Acute Toxic Class Method, 2000 mg/kg of the undiluted test item 3-(1-Ethoxyethyl)-5-methyloxazolidin-2-on were administered by gavage to two test groups of three fasted Wistar rats each (6 females). The following test substance-related clinical observations were recorded, clinical signs occurred within six days after administration.
In the first test group (2000 mg/kg) no mortality occurred, impaired general state in all animals, poor general state in two animals, piloerection in all animals, dyspnoea in all animals, abdominal position in one animal, lateral position in one animal, cowering position in one animal, lacrimation in two animals, salivation in two animals, chromodacryorrhea in one animal, atonia in one animal, tremor in one animal, clonic convulsions in one animal, exsiccosis in one animal and reduced defecation in two animals. In the second test group (2000 mg/kg) no mortality occurred, impaired general state in all animals, poor general state in all animals, piloerection in all animals, dyspnoea in all animals, abdominal position in two animals, cowering position in all animals, ataxia in one animal and tremor in one animal. The body weight of one animal in each test group increased within the normal range throughout the study period. The body weights of the two other animals in both test group increased in a normal range during the first observation week but these animals only slightly gained weight during the second week. This effect is observed at times in the rat strain used, because in the required age range the female animals have already reached the phase of slow growth. There were no macroscopic pathological findings in any animal sacrificed at the end of the observation period (6 females). Under the conditions of this study the median lethal dose of 3-(1-Ethoxyethyl)-5-methyloxazolidin-2-on after oral administration was found to be greater than 2000 mg/kg bw in rats.
Justification for classification or non-classification
Based on the results, the test item is no subject to classification and labelling according to Regulation (EC) No 1272/2008 (CLP).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.